Nuclear medicine and information systems vendor ADAC Laboratoriesreported sharply higher sales and net income for its second quarter(end-March). The Milpitas, CA, company posted revenues of $58.4million, a company record, compared with revenues of $44.7
Nuclear medicine and information systems vendor ADAC Laboratoriesreported sharply higher sales and net income for its second quarter(end-March). The Milpitas, CA, company posted revenues of $58.4million, a company record, compared with revenues of $44.7 millionin the second quarter of 1995. Net income rose to $3.9 million,compared with $2.8 million in the corresponding period a yearago.
Bookings also increased, jumping 36% to $61 million and addingto the company's backlog. Nuclear medicine product bookings were$40 million for the quarter, a strong increase over the $31 millionin the same period last year but lower than the $48 million inthe first quarter of 1996. ADAC chairman and CEO David Lowe saidthat the drop was most likely due to a seasonal softening of theU.S. nuclear medicine market, as well as a reduction in servicecontract renewals commonly experienced in the second quarter.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.